Immune checkpoint inhibitors for patients with cancer may be associated with an increased risk for psoriasis when compared ...
Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka”) (Nasdaq: ORKA), a clinical stage ...
A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...
Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...
Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first ...
Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing peptide-based drugs, stands at a pivotal juncture in its ...
GlobalData on MSN2d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trialUS-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...
Super Bowl LIX champion Dallas Goedert of the Philadelphia Eagles shares his journey with plaque psoriasis. After 20 years of ...
Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback